Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study

Inclusion Criteria:

• Patient is currently receiving treatment with ceritinib within a Novartis-sponsoredstudy which has fulfilled the requirements for the primary objective and, in theopinion of the Investigator, would benefit from continued treatment.

• Patient has demonstrated compliance, as assessed by the investigator, with theparent study protocol requirements.

• Willingness and ability to comply with scheduled visits, treatment plans and anyother study procedures.

• Written informed consent obtained prior to enrolling in the roll-over study andreceiving study medication. If consent cannot be expressed in writing, it must beformally documented and witnessed via an independent trusted witness.

Exclusion Criteria:

• Patient has been permanently and prematurely discontinued from ceritinib studytreatment in the parent study due to any reason.

• Patient currently has unresolved toxicities for which ceritinib dosing has beeninterrupted in the parent study.

• Pregnant or nursing (lactating) women, where pregnancy is defined as the state of afemale after conception and until the termination of gestation, confirmed by apositive serum hCG laboratory test.

• Women of child-bearing potential, defined as all women physiologically capable ofbecoming pregnant, unless they are using highly effective methods of contraceptionduring dosing and for 3 months afer stopping ceritinib treatment.

• Sexually active males unless they use a condom during intercourse while taking drugand for 3 months after stopping ceritinib and should not father a child for at least 3 months after the last dose of treatment.